scholarly journals Low-risk papillary thyroid carcinoma

2019 ◽  
Vol 98 (6) ◽  
pp. 403-407
Author(s):  
Caio Nassuo Furukawa ◽  
Leonardo André Hage Fabri ◽  
Flávio Carneiro Hojaij

Introduction: A epidemic increase in the incidence of papillary thyroid carcinoma (PTC) has been happening within the last 25 years. The majority of those tumors are low-risk, and some studies reported low progression rates of low-risk PTC. It suggests that immediate surgery may not be the best option, specially when considering the intrinsic risk to a thyroidectomy and inconvenience of lifelong hormone replacement. In this systematic review we compare the outcomes of active surveillance for the primary management of low-risk PTC. Methods: The review was conducted based on three studies selected from specific databases. These studies followed up low-risk patients nonoperatively and surgery was performed if needed. Results: All studies reported low percentages of tumor growth and metastatic disease during active surveillance. Furthermore, no significant differences between immediate surgery and late rescue surgery were reported, and active surveillance appears to be cheaper than the tradicional conduct. Conclusions: Active surveillance seems to be a good alternative for low-risk PTC management, yet, more long-term and bigger research is still needed, specially outside of a japanese population.

2016 ◽  
Vol 82 (9) ◽  
pp. 807-814 ◽  
Author(s):  
Paritosh Suman ◽  
Chi-Hsiung Wang ◽  
Tricia A. Moo-Young ◽  
Richard A. Prinz ◽  
David J. Winchester

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71–1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC.


2020 ◽  
Vol 146 (6) ◽  
pp. 552 ◽  
Author(s):  
Alexandra Koshkina ◽  
Rouhi Fazelzad ◽  
Iwao Sugitani ◽  
Akira Miyauchi ◽  
Lehana Thabane ◽  
...  

2017 ◽  
Vol 2 ◽  
pp. 10-10
Author(s):  
Gianluca Donatini ◽  
Beatriz De Rienzo ◽  
Jean Louis Kraimps

Sign in / Sign up

Export Citation Format

Share Document